BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34481947)

  • 1. Increased immunogenicity and protection of recombinant Sm14 antigens by heat-killed Cutibacterium acnes in BALB/c mice infected with Schistosoma mansoni.
    Lam HYP; Huang SP; Liang TR; Wu WJ; Cheng PC; Chang KC; Peng SY
    Parasitol Int; 2022 Feb; 86():102446. PubMed ID: 34481947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection.
    Ewaisha RE; Bahey-El-Din M; Mossallam SF; Amer EI; Aboushleib HM; Khalil AM
    Exp Parasitol; 2014 Oct; 145():51-60. PubMed ID: 25092439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone.
    Fonseca CT; Pacífico LG; Barsante MM; Rassi T; Cassali GD; Oliveira SC
    Microbes Infect; 2006 Aug; 8(9-10):2509-16. PubMed ID: 16914349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat-killed Propionibacterium acnes augment the protective effect of 28-kDa glutathione S-transferases antigen against Schistosoma mansoni infection.
    Lam HYP; Yang TH; Liang TR; Cheng PC; Chang KC; Peng SY
    Acta Trop; 2021 Oct; 222():106033. PubMed ID: 34224719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge.
    Varaldo PB; Leite LC; Dias WO; Miyaji EN; Torres FI; Gebara VC; Armôa GR; Campos AS; Matos DC; Winter N; Gicquel B; Vilar MM; McFadden J; Almeida MS; Tendler M; McIntosh D
    Infect Immun; 2004 Jun; 72(6):3336-43. PubMed ID: 15155638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of immunization with recombinant Sm14 (rSm14) in reducing worm burden and mortality of mice infected with Schistosoma mansoni.
    Ribeiro F; Vieira Cdos S; Fernandes A; Araujo N; Katz N
    Rev Soc Bras Med Trop; 2002; 35(1):11-7. PubMed ID: 11873255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection.
    Espíndola MS; Frantz FG; Soares LS; Masson AP; Tefé-Silva C; Bitencourt CS; Oliveira SC; Rodrigues V; Ramos SG; Silva CL; Faccioli LH
    BMC Infect Dis; 2014 May; 14():263. PubMed ID: 24886395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate.
    Ramos CR; Spisni A; Oyama S; Sforça ML; Ramos HR; Vilar MM; Alves AC; Figueredo RC; Tendler M; Zanchin NI; Pertinhez TA; Ho PL
    Biochim Biophys Acta; 2009 Apr; 1794(4):655-62. PubMed ID: 19150418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.
    Abreu PA; Miyasato PA; Vilar MM; Dias WO; Ho PL; Tendler M; Nascimento AL
    Infect Immun; 2004 Oct; 72(10):5931-7. PubMed ID: 15385496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. r-Sm14 - pRSETA efficacy in experimental animals.
    Ramos CR; Vilar MM; Nascimento AL; Ho PL; Thaumaturgo N; Edelenyi R; Almeida M; Dias WO; Diogo CM; Tendler M
    Mem Inst Oswaldo Cruz; 2001; 96 Suppl():131-5. PubMed ID: 11586438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene structure and M20T polymorphism of the Schistosoma mansoni Sm14 fatty acid-binding protein. Molecular, functioanl, and immunoprotection analysis.
    Ramos CR; Figueredo RC; Pertinhez TA; Vilar MM; do Nascimento AL; Tendler M; Raw I; Spisni A; Ho PL
    J Biol Chem; 2003 Apr; 278(15):12745-51. PubMed ID: 12551912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model.
    Mossallam SF; Amer EI; Ewaisha RE; Khalil AM; Aboushleib HM; Bahey-El-Din M
    BMC Infect Dis; 2015 Mar; 15():147. PubMed ID: 25887456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant Mycobacterium bovis Bacille Calmette-Guérin enhances protein expression but not protection against cercarial challenge in mice.
    Varaldo PB; Miyaji EN; Vilar MM; Campos AS; Dias WO; Armôa GR; Tendler M; Leite LC; McIntosh D
    FEMS Immunol Med Microbiol; 2006 Oct; 48(1):132-9. PubMed ID: 16965361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults.
    Santini-Oliveira M; Coler RN; Parra J; Veloso V; Jayashankar L; Pinto PM; Ciol MA; Bergquist R; Reed SG; Tendler M
    Vaccine; 2016 Jan; 34(4):586-594. PubMed ID: 26571311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis.
    Fonseca CT; Cunha-Neto E; Goldberg AC; Kalil J; de Jesus AR; Carvalho EM; Correa-Oliveira R; Oliveira SC
    Microbes Infect; 2005 Feb; 7(2):204-12. PubMed ID: 15725385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice.
    Garcia TC; Fonseca CT; Pacifico LG; Durães Fdo V; Marinho FA; Penido ML; Caliari MV; de Melo AL; Pinto HA; Barsante MM; Cunha-Neto E; Oliveira SC
    Acta Trop; 2008 Jun; 106(3):162-7. PubMed ID: 18423420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway.
    Fonseca CT; Brito CF; Alves JB; Oliveira SC
    Vaccine; 2004 Jan; 22(3-4):503-10. PubMed ID: 14670333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine.
    Tendler M; Simpson AJ
    Acta Trop; 2008; 108(2-3):263-6. PubMed ID: 18834847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine.
    Tendler M; Brito CA; Vilar MM; Serra-Freire N; Diogo CM; Almeida MS; Delbem AC; Da Silva JF; Savino W; Garratt RC; Katz N; Simpson AS
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):269-73. PubMed ID: 8552619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-gamma and tumour necrosis factor-alpha in response to the recombinant 14KDA Schistosoma mansoni fatty acid-binding protein.
    Brito CF; Caldas IR; Coura Filho P; Correa-Oliveira R; Oliveira SC
    Scand J Immunol; 2000 Jun; 51(6):595-601. PubMed ID: 10849370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.